Begin main content

Halobetasol propionate and tazarotene

Last Updated: February 19, 2020
Result type: Reports
Project Number: SR0638-000
Product Line: Common Drug Review

Generic Name: Halobetasol propionate and tazarotene

Brand Name: Duobrii

Manufacturer: Bausch Health, Canada Inc.

Indications: Psoriasis, moderate to severe plaque

Manufacturer Requested Reimbursement Criteria1: Improving the signs and symptoms of plaque psoriasis in adult patients with moderate to severe plaque psoriasis.

Submission Type: New Combination

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input open December 19, 2019
Call for patient input closed February 14, 2020
Clarification:

- Patient input submission received from Canadian Psoriasis Network (CPN), Canadian Skin Patient Alliance (CSPA) and the Canadian Association of Psoriasis Patients (CAPP)

Submission received January 24, 2020
Submission accepted February 07, 2020
Review initiated February 10, 2020
Draft CADTH review report(s) provided to sponsor for comment April 24, 2020
Deadline for sponsors comments May 05, 2020
CADTH responses on draft review report(s) provided to sponsor June 05, 2020
Expert committee meeting (initial) June 17, 2020
Draft recommendation issued June 29, 2020
To
July 02, 2020